LGALS3 and non-small cell lung carcinoma: GB1211 has high affinity for galectin-3 (0.025 ± 0.0017 μM) with good oral bioavailability in animals (68% in mice) [27] and is currently in development for the treatment of cancer and fibrotic disorders including NSCLC (identifier: NCT05240131) and cirrhosis (identifier: NCT05009680), respectively [5].